Artiva Biotherapeutics (NASDAQ:ARTV) Director Acquires $247,693.92 in Stock

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Director Ra Capital Management, L.P. purchased 24,944 shares of the firm’s stock in a transaction that occurred on Friday, July 31st. The stock was purchased at an average price of $9.93 per share, with a total value of $247,693.92. Following the purchase, the director directly owned 17,329,570 shares of the company’s stock, valued at $172,082,630.10. The trade was a 0.14% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Wednesday, July 29th, Ra Capital Management, L.P. acquired 20,824 shares of Artiva Biotherapeutics stock. The stock was purchased at an average cost of $9.99 per share, for a total transaction of $208,031.76.
• On Friday, July 24th, Ra Capital Management, L.P. acquired 41,319 shares of Artiva Biotherapeutics stock. The stock was purchased at an average cost of $9.99 per share, for a total transaction of $412,776.81.
• On Thursday, July 23rd, Ra Capital Management, L.P. acquired 59,880 shares of Artiva Biotherapeutics stock. The stock was purchased at an average price of $9.96 per share, for a total transaction of $596,404.80.
• On Wednesday, July 22nd, Ra Capital Management, L.P. acquired 84,124 shares of Artiva Biotherapeutics stock. The shares were purchased at an average cost of $9.93 per share, with a total value of $835,351.32.
• On Tuesday, July 21st, Ra Capital Management, L.P. acquired 120,582 shares of Artiva Biotherapeutics stock. The shares were purchased at an average cost of $9.55 per share, with a total value of $1,151,558.10.
• On Friday, July 10th, Ra Capital Management, L.P. bought 15,102 shares of Artiva Biotherapeutics stock. The shares were purchased at an average price of $8.97 per share, with a total value of $135,464.94.
• On Monday, July 13th, Ra Capital Management, L.P. bought 6,552 shares of Artiva Biotherapeutics stock. The stock was acquired at an average cost of $8.94 per share, for a total transaction of $58,574.88.
• On Friday, June 26th, Ra Capital Management, L.P. bought 1,876 shares of Artiva Biotherapeutics stock. The stock was acquired at an average cost of $8.98 per share, for a total transaction of $16,846.48.
• On Thursday, June 25th, Ra Capital Management, L.P. purchased 31,000 shares of Artiva Biotherapeutics stock. The stock was acquired at an average price of $8.88 per share, for a total transaction of $275,280.00.
• On Tuesday, June 16th, Ra Capital Management, L.P. purchased 124,893 shares of Artiva Biotherapeutics stock. The shares were acquired at an average cost of $8.89 per share, with a total value of $1,110,298.77.

Artiva Biotherapeutics Stock Performance

NASDAQ ARTV traded down $0.33 during trading on Friday, reaching $10.10. 360,712 shares of the company’s stock were exchanged, compared to its average volume of 388,730. The company has a 50 day moving average price of $8.96 and a two-hundred day moving average price of $7.49. The stock has a market cap of $249.64 million, a P/E ratio of -2.85 and a beta of 2.18. Artiva Biotherapeutics, Inc. has a 1 year low of $2.22 and a 1 year high of $14.53.

Artiva Biotherapeutics (NASDAQ:ARTV) last released its quarterly earnings data on Friday, May 8th. The company reported ($0.95) EPS for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.07). Research analysts forecast that Artiva Biotherapeutics, Inc. will post -2.45 EPS for the current fiscal year.

Hedge Funds Weigh In On Artiva Biotherapeutics

A number of institutional investors have recently modified their holdings of the business. Prelude Capital Management LLC acquired a new stake in Artiva Biotherapeutics during the 3rd quarter worth $41,000. Bank of America Corp DE increased its stake in Artiva Biotherapeutics by 225.8% in the third quarter. Bank of America Corp DE now owns 16,145 shares of the company’s stock valued at $46,000 after purchasing an additional 11,190 shares during the period. Bridgeway Capital Management LLC acquired a new position in Artiva Biotherapeutics in the second quarter valued at $53,000. Qube Research & Technologies Ltd purchased a new stake in shares of Artiva Biotherapeutics in the second quarter valued at about $58,000. Finally, Jane Street Group LLC acquired a new stake in shares of Artiva Biotherapeutics during the second quarter worth about $67,000.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on ARTV shares. Needham & Company LLC reiterated a “buy” rating and issued a $41.00 price target on shares of Artiva Biotherapeutics in a research note on Monday, June 8th. Cantor Fitzgerald restated an “overweight” rating on shares of Artiva Biotherapeutics in a research report on Tuesday, May 26th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research report on Tuesday, July 21st. HC Wainwright lifted their price target on shares of Artiva Biotherapeutics from $15.00 to $35.00 and gave the stock a “buy” rating in a research note on Friday, May 8th. Finally, Wall Street Zen cut shares of Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, May 17th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $39.00.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.